Adjuvant Therapy Options in Melanoma Treatment

Source: OncLive, September 2019

Sanjiv S. Agarwala, MD: Let’s talk about something now that is available to us: adjuvant therapy. It’s the other side of the spectrum. A lot of data have come out recently. I think I’ll start with you, Dr Robert.

Caroline Robert, MD, PhD: Explosion of clinical trials.

Sanjiv S. Agarwala, MD: Exactly. Let me turn to you for discussion regarding the usual trials: KEYNOTE-054 with pembrolizumab, CheckMate 238 with nivolumab, and then COMBI-AD. These are all well-known trials, [with] good data, and available. What are your thoughts of adjuvant therapy? How do you pick? Let’s start with you.